These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37594592)

  • 21. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
    Mak WY; Ooi QX; Cruz CV; Looi I; Yuen KH; Standing JF
    Br J Clin Pharmacol; 2023 Jan; 89(1):330-339. PubMed ID: 35976674
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.
    Tod M; Padoin C; Louchahi K; Moreau-Tod B; Petitjean O; Perret G
    J Pharmacokinet Biopharm; 1994 Apr; 22(2):129-46. PubMed ID: 7815309
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmacokinetic models and design of a Bayesian estimator.
    Rousseau A; Léger F; Le Meur Y; Saint-Marcoux F; Paintaud G; Buchler M; Marquet P
    Ther Drug Monit; 2004 Feb; 26(1):23-30. PubMed ID: 14749545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimation of population pharmacokinetic parameters in the presence of non-compliance.
    Mu S; Ludden TM
    J Pharmacokinet Pharmacodyn; 2003 Feb; 30(1):53-81. PubMed ID: 12800807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model.
    Lahu G; Hünnemeyer A; Diletti E; Elmlinger M; Ruth P; Zech K; McCracken N; Facius A
    Clin Pharmacokinet; 2010 Sep; 49(9):589-606. PubMed ID: 20690782
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, absolute bioavailability, and absorption characteristics of lamivudine.
    Yuen GJ; Morris DM; Mydlow PK; Haidar S; Hall ST; Hussey EK
    J Clin Pharmacol; 1995 Dec; 35(12):1174-80. PubMed ID: 8750368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Revising Pharmacokinetics of Oral Drug Absorption: II Bioavailability-Bioequivalence Considerations.
    Chryssafidis P; Tsekouras AA; Macheras P
    Pharm Res; 2021 Aug; 38(8):1345-1356. PubMed ID: 34341958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPK) Models.
    Chryssafidis P; Tsekouras AA; Macheras P
    Pharm Res; 2022 Apr; 39(4):691-701. PubMed ID: 35378697
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship Between Dissolution Rate in Vitro and Absorption Rate in Vivo of Ketamine Prolonged-Release Tablets.
    Weiss M
    Eur J Drug Metab Pharmacokinet; 2023 Mar; 48(2):133-140. PubMed ID: 36646846
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.
    Maung NH; Methaneethorn J; Wattanavijitkul T; Sriboonruang T
    Eur J Hosp Pharm; 2022 Mar; 29(e1):e57-e62. PubMed ID: 34285111
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationships between half-life (t1/2) and mean residence time (MRT) in the two-compartment open body model.
    Sobol E; Bialer M
    Biopharm Drug Dispos; 2004 May; 25(4):157-62. PubMed ID: 15108218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic properties of ethosuximide in monkeys. I. Single-dose intravenous and oral administration.
    Patel IH; Levy RH; Bauer TG
    Epilepsia; 1975 Dec; 16(5):705-16. PubMed ID: 816644
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies.
    Savic RM; Jonker DM; Kerbusch T; Karlsson MO
    J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):711-26. PubMed ID: 17653836
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bias in the Wagner-Nelson estimate of the fraction of drug absorbed.
    Wang Y; Nedelman J
    Pharm Res; 2002 Apr; 19(4):470-6. PubMed ID: 12033382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Modelling of Acetaminophen and Ibuprofen: the Influence of Body Composition, Formulation and Feeding in Healthy Adult Volunteers.
    Morse JD; Stanescu I; Atkinson HC; Anderson BJ
    Eur J Drug Metab Pharmacokinet; 2022 Jul; 47(4):497-507. PubMed ID: 35366213
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stepwise determination of multicompartment disposition and absorption parameters from extravascular concentration-time data. Application to mesoridazine, flurbiprofen, flunarizine, labetalol, and diazepam.
    Wagner JG; Ganes DA; Midha KK; Gonzalez-Younes I; Sackellares JC; Olson LD; Affrime MB; Patrick JE
    J Pharmacokinet Biopharm; 1991 Aug; 19(4):413-55. PubMed ID: 1920088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quinidine pharmacokinetics in man: choice of a disposition model and absolute bioavailability studies.
    Guentert TW; Holford NH; Coates PE; Upton RA; Riegelman S
    J Pharmacokinet Biopharm; 1979 Aug; 7(4):315-30. PubMed ID: 512840
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.
    Piotrovskij V; Van Peer A
    Pharm Res; 1997 Feb; 14(2):230-7. PubMed ID: 9090715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.
    Golabchifar AA; Rezaee S; Dinan NM; Kebriaeezadeh A; Rouini MR
    Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):527-39. PubMed ID: 26189007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.